Adrenocortical carcinoma staging: Difference between revisions
No edit summary |
|||
(23 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Adrenocortical carcinoma}} | {{Adrenocortical carcinoma}} | ||
{{CMG}}; {{AE}} {{AAM}} {{MAD}} | |||
==Overview== | |||
According to the [[TNM staging system]], there are four stages of adrenocortical cancer based on the [[tumor]] size, [[lymph nodes]], and distant [[metastasis]]. Each stage is assigned a number and letter that designates the number of [[lymph nodes]] involved and presence/absence of [[Metastasis|distant metastasis]]. | |||
==Staging of adrenocortical carcinoma== | |||
The AJCC has designated staging by [[TNM Staging System|TNM]] to define adrenocortical carcinoma: <ref name="pmid20180029">{{cite journal| author=Edge SB, Compton CC| title=The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. | journal=Ann Surg Oncol | year= 2010 | volume= 17 | issue= 6 | pages= 1471-4 | pmid=20180029 | doi=10.1245/s10434-010-0985-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20180029 }}</ref> | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | |||
|+'''''Adrenal cancer TNM staging''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Description}} | |||
|- | |||
! style="background: #DCDCDC;" |TX | |||
! style="background: #F5F5F5;" |Primary [[tumor]] cannot be assessed | |||
|- | |||
! style="background: #DCDCDC;" |T0 | |||
! style="background: #F5F5F5;" |No evidence of primary [[tumor]] | |||
|- | |||
! style="background: #DCDCDC;" |T1 | |||
! style="background: #F5F5F5;" |[[Tumor]] ≤5 cm in greatest dimension limited to the [[thyroid|adrenals]] | |||
|- | |||
! style="background: #DCDCDC;" |T2 | |||
! style="background: #F5F5F5;" |[[Tumor]] >5 cm in greatest dimension, limited to the adrenals | |||
|- | |||
! style="background: #DCDCDC;" |T3 | |||
! style="background: #F5F5F5;" |Tumor of any size with local invasion, but not invading adjacent organs | |||
|- | |||
! style="background: #DCDCDC;" |T4 | |||
! style="background: #F5F5F5;" |Tumor of any size with invasion of adjacent organs | |||
|} | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | |||
|+'''''Regional Lymph Nodes (N)''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Description}} | |||
|- | |||
! style="background: #DCDCDC;" |NX | |||
! style="background: #F5F5F5;" |Regional [[lymph node]] cannot be assessed | |||
|- | |||
! style="background: #DCDCDC;" |N0 | |||
! style="background: #F5F5F5;" |No regional lymph node metastasis | |||
|- | |||
! style="background: #DCDCDC;" |N1 | |||
! style="background: #F5F5F5;" |Regional [[lymph node]] metastasis | |||
|} | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | |||
|+'''''Distant Metastasis (M)''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Description}} | |||
|- | |||
! style="background: #DCDCDC;" |M0 | |||
! style="background: #F5F5F5;" |No distant [[metastasis]] | |||
|- | |||
! style="background: #DCDCDC;" |M1 | |||
! style="background: #F5F5F5;" |Distant [[metastasis]] | |||
|} | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | |||
|+'''''Anatomic Stage/Prognostic Groups''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|T}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|N}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|M}} | |||
|- | |||
! style="background: #DCDCDC;" |I | |||
! style="background: #F5F5F5;" |T1 | |||
! style="background: #F5F5F5;" |N0 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" |II | |||
! style="background: #F5F5F5;" |T2 | |||
! style="background: #F5F5F5;" |N0 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" |III | |||
! style="background: #F5F5F5;" |T1 | |||
! style="background: #F5F5F5;" |N1 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" | | |||
! style="background: #F5F5F5;" |T2 | |||
! style="background: #F5F5F5;" |N1 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" | | |||
! style="background: #F5F5F5;" |T3 | |||
! style="background: #F5F5F5;" |N0 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! style="background: #DCDCDC;" |IV | |||
! style="background: #F5F5F5;" |T3 | |||
! style="background: #F5F5F5;" |N1 | |||
! style="background: #F5F5F5;" |M0 | |||
|- | |||
! | |||
!T4 | |||
!N0 | |||
!M0 | |||
|- | |||
! | |||
!T4 | |||
!N1 | |||
!M0 | |||
|- | |||
! | |||
!Any T | |||
!Any N | |||
!M1 | |||
|} | |||
A new study showed staging system that incorporates the patient's age better and predicts 5-year survival among patients with stages I/II ACC. Consideration should be given to include age in staging for ACC, because it may better inform providers about treatment and prognosis.<ref name="pmid25456914">{{cite journal| author=Asare EA, Wang TS, Winchester DP, Mallin K, Kebebew E, Sturgeon C| title=A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease. | journal=Surgery | year= 2014 | volume= 156 | issue= 6 | pages= 1378-85; discussion 1385-6 | pmid=25456914 | doi=10.1016/j.surg.2014.08.018 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25456914 }}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:54, 30 October 2017
Adrenocortical carcinoma Microchapters |
Differentiating Adrenocortical carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Study |
Adrenocortical carcinoma staging On the Web |
American Roentgen Ray Society Images of Adrenocortical carcinoma staging |
Risk calculators and risk factors for Adrenocortical carcinoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
According to the TNM staging system, there are four stages of adrenocortical cancer based on the tumor size, lymph nodes, and distant metastasis. Each stage is assigned a number and letter that designates the number of lymph nodes involved and presence/absence of distant metastasis.
Staging of adrenocortical carcinoma
The AJCC has designated staging by TNM to define adrenocortical carcinoma: [1]
Stage | Description |
---|---|
TX | Primary tumor cannot be assessed |
T0 | No evidence of primary tumor |
T1 | Tumor ≤5 cm in greatest dimension limited to the adrenals |
T2 | Tumor >5 cm in greatest dimension, limited to the adrenals |
T3 | Tumor of any size with local invasion, but not invading adjacent organs |
T4 | Tumor of any size with invasion of adjacent organs |
Stage | Description |
---|---|
NX | Regional lymph node cannot be assessed |
N0 | No regional lymph node metastasis |
N1 | Regional lymph node metastasis |
Stage | Description |
---|---|
M0 | No distant metastasis |
M1 | Distant metastasis |
Stage | T | N | M |
---|---|---|---|
I | T1 | N0 | M0 |
II | T2 | N0 | M0 |
III | T1 | N1 | M0 |
T2 | N1 | M0 | |
T3 | N0 | M0 | |
IV | T3 | N1 | M0 |
T4 | N0 | M0 | |
T4 | N1 | M0 | |
Any T | Any N | M1 |
A new study showed staging system that incorporates the patient's age better and predicts 5-year survival among patients with stages I/II ACC. Consideration should be given to include age in staging for ACC, because it may better inform providers about treatment and prognosis.[2]
References
- ↑ Edge SB, Compton CC (2010). "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM". Ann Surg Oncol. 17 (6): 1471–4. doi:10.1245/s10434-010-0985-4. PMID 20180029.
- ↑ Asare EA, Wang TS, Winchester DP, Mallin K, Kebebew E, Sturgeon C (2014). "A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease". Surgery. 156 (6): 1378–85, discussion 1385-6. doi:10.1016/j.surg.2014.08.018. PMID 25456914.